194
Participants
Start Date
January 7, 2019
Primary Completion Date
June 13, 2022
Study Completion Date
June 23, 2022
Emixustat
Once daily oral tablet taken for 24 months
Placebo
Once daily oral tablet taken for 24 months
Radboud University Medical Center, Nijmegen
IRCCS Ospedale San Raffaele, Milan
UOC Oculistica Asst Fatebene Pratelli Sacco Universita delgi Studi di Milano, Milan
The Wilmer Eye Institute Johns Hopkins University, Baltimore
Duke Eye Center, Durham
Fundacion Jimenez Diaz University Hospital, Madrid
Emory University, Atlanta
University of Michigan Kellogg Eye Center, Ann Arbor
SODC di Oculistica AOU Careggi, Florence
Universitäts-Augenklinik Bonn, Bonn
Medical College of Wisconsin-Eye Institute, Milwaukee
Mayo Clinic Rochester, Rochester
Universitätsklinikum Tübingen, Department für Augenheilkunde, Tübingen
CHNO Quinze-Vingts - CIC, Paris
Retina Foundation of the Southwest, Dallas
AOU Università della Campania Luigi Vanvitelli, Naples
University of Utah John Moran Eye Center, Salt Lake City
Retina-Vitreous Associates Medical Group, Beverly Hills
Service D'Ophtalmologie Chi Creteil, Créteil
Casey Eye Institute - OHSU, Portland
UCSF Dept. of Ophthalmology, San Francisco
Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte
Hospital Sao Paulo, São Paulo
The Hospital for Sick Children, Toronto
Rigshospitalet-Glostrup, Glostrup Municipality
Università Cattolica del Sacro Cuore - Fondazione Policlinico Gemelli, Rome
Pretoria Eye Institute, Pretoria
Oxford Eye Hospital,Oxford University Hospitals NHS Foundation Trust, Oxford
Moorfields Eye Hospital NHS Foundation Trust, London
Lead Sponsor
Food and Drug Administration (FDA)
FED
Kubota Vision Inc.
INDUSTRY